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Abstract 
Nanomaterials (NMs) are currently being used for a wide variety of products, and a number of them are 
utilized as biocides due to their antimicrobial or antifungal properties. Little is known to what extent these 
biocides are available on the market as consumer products. In the EU, Biocidal Product Regulation (BPR) is 
laying out a list of requirements that manufacturers of biocidal products have to comply with before they 
can place their products on the market. It is not entirely clear which commercially available articles in the 
EU that have been treated with or incorporate NMs to provide biocidal properties to the product. To obtain 
an insight into what biocidal products are on the EU market, we used The Nanodatabase (nanodb.dk) for 
analyzing which NMs are being used and what product categories they represent. In this paper, we are 
addressing the issue of current uses of NMs in biocidal products and discussing how they are currently 
regulated under the BPR. Even though BPR already entails nanospecific provisions, correct labelling of 
biocidal products containing NMs is virtually non-existent. By using The Nanodatabase it was possible to 
identify 88 biocidal products containing NMs available on the EU market, none of which had the specific 
labelling required by BPR. The analysis of biocidal products pinpoints the challenges and limitations for 
obtaining a reasonable overview of the current uses of NMs in biocidal products as defined in the BPR. 
  
1. Introduction 
Many nanomaterials (NMs) are used in consumer products due to their biocidal activity, e.g. the 
antibacterial properties of nanosilver and nanocopper are exploited in various products such as antifouling 
paints, cleaning products, socks, toothbrushes, and many others.  
 Biocides are chemicals, which are used to control and suppress the growth of unwanted 
organisms that are harmful to human or animal health, or damaging to human activities.1 Metals have been 
utilized for their antimicrobial properties for centuries2 and these properties may be enhanced when the 
size of the material is reduced to the nanoscale,3 because that provides greater reactivity when compared 
to larger particles. 4 
In 2013, the Biocidal Product Regulation (BPR) went into force in Europe, and the BPR sets 
out very specific requirements for biocidal products and treated articles that producers have to comply 
with before they can place their products on the market. When it comes to nanomaterials, these 
requirements include having to prepare a specific risk assessment for the nanomaterial in question in order 
to get an authorization for a biocidal product that contains nanomaterials. Nano-specific BPR requirements 
are needed to better regulate the nanomaterials in consumer products and make sure they are safe before 
they reach the market. 
Very little is known to what extent nanomaterials are used in biocidal products and in 
treated articles. In order to address this knowledge gap, we analyzed the current list of approved active 
substances within the BPR for substances that might potentially be in nanoforms as well as the list of 
substances that are currently undergoing evaluation and that have not yet been approved. Furthermore, in 
order to map the use of nanomaterials in treated articles, we used The Nanodatabase5, which is an 
European database containing more than 2,300 consumer products claimed to contain nanomaterials 
and/or to be based on nanomaterials, to identify biocidal products and thereby investigate the current uses 
of nanomaterials for biocidal purposes in consumer products.  
In the following we will first provide a short overview of the BPR and the legislation that 
preceded it, namely the Biocidal Product Directive (BPD). Then we introduce the nanospecific provisions in 
the BPR with a specific focus on active substances, biocidal products and treated articles, which is followed 
by a discussion about the list of approved active substances as well as the list of existing active substances 
to be assessed under BPR, focusing on substances that either have been identified as nanomaterials or that 
might be nanomaterials. Finally, we present our analysis of biocidal products and treated articles currently 
listed in The Nanodatabase and pinpoint the challenges and limitations that currently hinder us for 
obtaining a full overview of the current uses of nanomaterials in biocidal products and treated articles as 
defined in the BPR.  
 
2. The Biocidal Product Regulation 
In 1993 the European Commission expressed the need for a legislation to regulate biocidal products on the 
European market by proposing the first legislative proposal on the subject. 6 Five years later the Directive 
concerning the placing of biocidal products on the market (Directive 98/8/EC) (BPD) was adopted.7 It was 
later reported that the directive had several weaknesses including the lack of provisions on nanomaterials,8 
and in order to address these and improve and update different elements of the Directive, the Commission 
proposed a new regulation; namely the European Biocidal Product Regulation (Regulation (EU) No 
528/2012) (BPR),9 which came into force in September 2013. The aim of the regulation is to improve the 
functioning of the internal market for biocidal products in the EU and at the same time to ensure a high 
level of protection for humans, animals and the environment.10 This means that all biocidal product 
manufacturers and importers must eventually seek authorization according to the procedures described in 
the BPR before placing a biocidal product on the European market.  
 
2.1.. Biocidal products 
In the BPR a biocidal product is defined as “any substance or mixture, in the form in which it is 
supplied to the user, consisting of, containing or generating one or more active substances, with the 
intention of destroying, deterring, rendering harmless, preventing the action of, or otherwise exerting a 
controlling effect on, any harmful organism by any means other than mere physical or mechanical action” 
(Art. 3, (a)).10 Substances or mixtures with biocidal activity, that are generated from a substance or mixture 
that do not themselves fall under the definition stated above (i.e. so-called in-situ generated substances) as 
well as treated articles with a primary biocidal function, are also considered as biocidal products according 
to the BPR.10 As seen from the definition, the main defining constituent of a biocidal product is the active 
substance, which again is defined as “a substance or a microorganism that has an action on or against 
harmful organisms”.10 Active substances are separated into existing active substances and new active 
substances, which are substances that were placed on the market as part of a biocidal product by May 14, 
2000 and substances, which were not on the market at that time, respectively. In order for a manufacturer 
to obtain authorization for a biocidal product through the BPR, two separate dossiers must be submitted: 
one for the active substance to be approved and one for the biocidal product (Art. 6).10 An approval of an 
active substance is restricted to a given biocidal product type (PT) (Art. 4),10 which means that if a 
manufacturer wishes to use an active substance in several different product types, then applications must 
be submitted for each active substance/product type combination within 2 years of the opinion on the 
approval of the active substance. See Table 1 for a list of the different product types under the BPR.  
 
Table 1: Different product types (PT) under the BPR, adapted from ECHA11. 
Number Product type Description 
Main group 1: Disinfectants 
These product types exclude cleaning products that are not intended to have a biocidal effect, including washing liquids, powders 
and similar products. 
PT 1 Human hygiene Products in this group are biocidal products used for human hygiene purposes, applied on or in 
contact with human skin or scalps for the primary purpose of disinfecting the skin or scalp. 
PT 2 Disinfectants and 
algaecides not 
intended for 
direct application 
Used for the disinfection of surfaces, materials, equipment and furniture which are not used for 
direct contact with food or feeding stuffs. Usage areas include, inter alia, swimming pools, 
aquariums, bathing and other waters; air conditioning systems; and walls and floors in private, 
public, and industrial areas and in other areas for professional activities. 
to humans or 
animals 
Used for disinfection of air, water not used for human or animal consumption, chemical toilets, 
waste water, hospital waste and soil. 
Used as algaecides for treatment of swimming pools, aquariums and other waters and for 
remedial treatment of construction materials. 
Used to be incorporated in textiles, tissues, masks, paints and other articles or materials with 
the purpose of producing treated articles with disinfecting properties. 
PT 3 Veterinary 
hygiene 
Used for veterinary hygiene purposes such as disinfectants, disinfecting soaps, oral or corporal 
hygiene products or with anti-microbial function. 
Used to disinfect the materials and surfaces associated with the housing or transportation of 
animals. 
PT 4 Food and feed 
area 
Used for the disinfection of equipment, containers, consumption utensils, surfaces or pipework 
associated with the production, transport, storage or consumption of food or feed (including 
drinking water) for humans and animals. 
Used to impregnate materials which may enter into contact with food. 
PT 5 Drinking water Used for the disinfection of drinking water for both humans and animals. 
Main group 2: Preservatives 
Unless otherwise stated these product-types include only products to prevent microbial and algal development. 
PT 6 Preservatives for 
products during 
storage 
Used for the preservation of manufactured products, other than foodstuffs, feeding stuffs, 
cosmetics or medicinal products or medical devices by the control of microbial deterioration to 
ensure their shelf life. 
Used as preservatives for the storage or use of rodenticide, insecticide or other baits. 
PT 7 Film 
preservatives 
Used for the preservation of films or coatings by the control of microbial deterioration or algal 
growth in order to protect the initial properties of the surface of materials or objects such as 
paints, plastics, sealants, wall adhesives, binders, papers, art works. 
PT 8 Wood 
preservatives 
Used for the preservation of wood, from and including the saw-mill stage, or wood products by 
the control of wood-destroying or wood-disfiguring organisms, including insects. This product 
type includes both preventive and curative products. 
PT 9 Fibre, leather, 
rubber and 
polymerised 
materials 
preservatives 
Used for the preservation of fibrous or polymerised materials, such as leather, rubber or paper 
or textile products by the control of microbiological deterioration. 
This product-type includes biocidal products which antagonise the settlement of micro-
organisms on the surface of materials and therefore hamper or prevent the development of 
odour and/or offer other kinds of benefits. 
PT 10 Construction 
material 
preservatives 
Used for the preservation of masonry, composite materials, or other construction materials 
other than wood by the control of microbiological and algal attack. 
PT 11 Preservatives for 
liquid-cooling 
and processing 
systems 
Used for the preservation of water or other liquids used in cooling and processing systems by 
the control of harmful organisms such as microbes, algae and mussels. 
Products used for the disinfection of drinking water or of water for swimming pools are not 
included in this product-type. 
PT 12 Slimicides Used for the prevention or control of slime growth on materials, equipment and structures, 
used in industrial processes, e.g. on wood and paper pulp, porous sand strata in oil extraction. 
PT 13 Working or 
cutting fluid 
preservatives 
Products to control microbial deterioration in fluids used for working or cutting metal, glass or 
other materials. 
Main group 3: Pest control 
PT 14 Rodenticides Used for the control of mice, rats or other rodents, by means other than repulsion or attraction. 
PT 15 Avicides Used for the control of birds, by means other than repulsion or attraction. 
PT 16 Molluscicides, 
vermicides and 
products to 
control other 
invertebrates 
Used for the control of molluscs, worms and invertebrates not covered by other product types, 
by means other than repulsion or attraction. 
PT 17 Piscicides Used for the control of fish, by means other than repulsion or attraction. 
PT 18 Insecticides, 
acaricides and 
products to 
control other 
arthropods 
Used for the control of arthropods (e.g. insects, arachnids and crustaceans), by means other 
than repulsion or attraction. 
PT 19 Repellents and 
attractants 
Used to control harmful organisms (invertebrates such as fleas, vertebrates such as birds, fish, 
rodents), by repelling or attracting, including those that are used for human or veterinary 
hygiene either directly on the skin or indirectly in the environment of humans or animals. 
PT 20 Control of other 
vertebrates 
Used for the control of vertebrates other than those already covered by the other product types 
of this main group, by means other than repulsion or attraction. 
Main group 4: Other biocidal products 
PT 21 Antifouling 
products 
Used to control the growth and settlement of fouling organisms (microbes and higher forms of 
plant or animal species) on vessels, aquaculture equipment or other structures used in water. 
PT 22 Embalming and 
taxidermist fluids 
Used for the disinfection and preservation of human or animal corpses, or parts thereof. 
 
The dossier for obtaining approval for the active substance must contain information on the 
following: 
 the applicant (i.e. the manufacturer or the importer),  
 the identity and physico-chemical properties of the substance,  
 physical hazards and respective characteristics,  
 method of detection and identification,  
 effectiveness against target organisms,  
 intended uses and exposure,  
 toxicological profile for humans and animals,  
 ecotoxicity studies,  
 environmental fate and behaviour,  
 measures necessary to protect humans, animals and the environment, 
 information on classification, labelling and packaging.  
 
The dossier requirements for the biocidal products are similar.12 The assessment of the submitted 
dossiers is performed by the evaluating competent authority, who has to prepare a draft Assessment 
Report (AR). The applicant then has 30 days to comment on the report, and the application is subsequently 
handed over to the Biocidal Products Committee under the European Chemicals Agency (ECHA) for their 
opinion on the draft AR. The AR is finalized under the Biocidal Products Committee from which a final 
decision on approval is made by the Commission and the Standing Committee on Biocidal Products (Art. 8 
& 9).10 Once an active substance is approved, it will appear on the Union list of approved active substances 
for biocidal products (the “positive list”), which is available on the European Commission’s website (Art. 9, 
(2)).10 The list also specifies the product type for which the active substance is approved.13 It should be 
noted that the review of existing active substances is a long process and not due for completion 
until 31 Dec 202414. Step two is to submit a product dossier within 2 years of the opinion of the active 
substance and get the biocidal product authorized, which can be achieved in several different ways: 
through a simplified authorization, national authorization, mutual recognition, union authorization or 
though the concept of product families.10  
 
2.2. Treated Articles  
Under the BPR a ‘treated article’ is defined as any substance, mixture or article, which has been 
treated with, or intentionally incorporates, one or more biocidal products. Treated articles include such 
products as antibacterial socks, t-shirts, food contact materials and many others. However, it should be 
noted that if a treated article has a primary biocidal function, it has to be considered a biocidal product (Art 
3). After 1 September 2016, treated articles should not be placed on the market unless all active substances 
contained in the biocidal products with which they were treated or which they incorporate are approved in 
accordance with the BPR (Article 58). In case a claim is made by the manufacturer of the treated article 
regarding its biocidal properties or the approval of the active substance(s) is associated with specific 
conditions, the treated article shall have a label that provides:  
 a statement that the treated article incorporates biocidal products;  
 where substantiated, the biocidal property attributed to the treated article e.g. antimicrobial;  
 the name of all active substances contained in the biocidal products;  
 if applicable, the name of all nanomaterials contained in the biocidal products, followed by the 
word ‘nano’ in brackets; 
 any relevant instructions for use, including any precautions to be taken, if this is necessary to 
protect humans, animals and the environment.  
The labelling shall be clearly visible, easily legible and appropriately durable (Article 58). Then labelling shall 
be printed either on the packaging, on the instructions for use or on the warranty (Article 58) and Member 
States shall make the necessary arrangements for the monitoring of biocidal products and treated articles 
which have been placed on the market to establish whether they comply with the requirements of this 
Regulation (Article 65).10 
The BPR also requires that substantial information related to the treated articles is submitted in 
order to obtain approval of an active substance. Core data that has to be provided includes likely 
concentration of the active substance, efficacy data, field of use(s), intended use pattern(s), information on 
exposure from treated articles including leaching data (either laboratory studies or model data), residues in 
or on treated articles, application rate and, if appropriate, the final concentration of the biocidal product 
and active substance in a treated article (see Title I of Annex II on information requirements for active 
substances).10    
  
3. Nano-specific provisions in the BPR 
The BPR is the first European piece of legislation to partly implement the recommended definition of NMs 
from the European Commission.15 The recommended definition defines a NM as “A natural, incidental or 
manufactured material containing particles, in an unbound state or as an aggregate or as an agglomerate 
and where, for 50 % or more of the particles in the number size distribution, one or more external 
dimensions is in the size range 1 nm-100 nm. In specific cases and where warranted by concerns for the 
environment, health, safety or competitiveness the number size distribution threshold of 50 % may be 
replaced by a threshold between 1 and 50 %”.15 It is important to note that Recital 14 of the Commission 
Recommendation states that definition should be subject to review in regard to the size distribution 
threshold of 50% as well as to whether to include materials with internal structure or surface structure in 
the nanoscale such as complex nanocomponent nanomaterials e.g nano-porous and nano-composite 
materials.  
Only the first part of the recommended definition is adopted by the BPR, in which a NM is defined 
as: “A natural or manufactured active substance or non-active substance containing particles, in an 
unbound state or as an aggregate or as an agglomerate and where, for 50 % or more of the particles in the 
number size distribution, one or more external dimension is in the size range 1-100 nm“ (Art. 3, (z)).10 Thus, 
the last part of the EU definition of NMs concerning the replacement of the 50% threshold by a lower one 
has been omitted in the BPR. The incidentally created NPs are omitted from the BPR definition of NMs as 
well. The definition of aggregates and agglomerates in the BPR is corresponding to the recommended 
definitions from the European Commission: “A particle comprising strongly bound or fused particles” and “A 
collection of weakly bound particles or aggregates where the resulting external surface area is similar to the 
sum of the surface areas of the individual components”, respectively. If a Member State is uncertain 
whether a substance is a NM, the final decision lays upon the European Commission according to the BPR. 
It is furthermore stated that the European Commission will have the power to adapt the definition a NM in 
the light of technical or scientific progress (Art. 3 (3 & 4)).10 
 Article 4 of the BPR states that an approval of an active substance does not cover the NM form as 
well, except in cases where it is explicitly mentioned (Art. 4).10 The argument for this provision relies on the 
fact that NMs are being used as a biocide because of their different properties compared to the bulk form 
of the same material, and these different properties may also result in different toxicities, which is why 
NMs require an assessment of their own. In order to obtain an authorization of a biocidal product that 
contains NMs, a specific risk assessment has to be performed for the NM in question (Art. 19).10 
Furthermore, due to current lack of adequate risk assessment of NMs, it is not possible to apply for a 
simplified authorization if the biocidal product contains NMs (Art. 25).10,16 The BPR also contains extensive 
requirements regarding labelling of biocidal products and treated articles. In addition to other information, 
all biocidal products containing NMs must have a label, stating that the product contains NMs, including 
the specific related risks of the NM and the word ‘nano’ in brackets following each reference to the given 
NM (Art. 69).10 For articles treated with a biocidal product containing NMs, labelling with information of the 
names of all NMs contained in the product, followed by the word ‘nano’ in brackets, is required (Art. 58).10 
The specific labelling provisions for these materials were included by the European Parliament due to the 
lack of knowledge regarding the impact of NMs on health and the environment, and the users of the 
biocidal products are therefore entitled to be correctly informed via adequate labelling.16 Once established 
on the market, Member States are furthermore obliged to monitor the Biocidal products and treated 
articles to make sure that they comply with the requirements of the BPR. Every five years each Member 
State must submit a report to the European Commission, which among other information must include 
details of the use of NMs in biocidal products and the potential risk thereof (Art. 65).10 
 
4. Nanomaterials and the list of approved active substances  
A company that wishes to use a given nanomaterial in a biocidal product has to obtain the approval, and 
the granted approval for the active substance must apply to the nanoforms of that active substance, except 
where explicitly stated otherwise. Hence, the current list of approved substances, and those substances 
being examined under the Review Programme, gives a good indication as to which kinds of nanomaterials 
might be used in biocidal products in the EU and therefore might be subject to nano-specific BPR 
requirements. This list currently contains basic copper carbonate, boric oxide, copper (II) oxide and copper 
hydroxide, which are commercially available in the nanoform (see, for instance, the Nanowerk’s 
Nanomaterials database17). For most of these materials, it is unknown whether the nanoform is being sold 
as a biocidal ingredient in Europe, although some are clearly being marketed as such, such as the “biocidal 
copper carbonate nanoparticles” sold by the German company nanoSaar.  
So far, only one type of NM has been approved as an active substance, namely synthetic 
amorphous silicone dioxide (SAS). SAS is approved as an active substance in product type 18 (insecticides). 
Although SAS should in theory be evaluated based on the data requirements of the BPD, SAS was in reality 
also evaluated in the light of the BPR when it comes to nanomaterials. For instance, according to the 
assessment report, SAS is a NM based on the definition in article 3(z) in the BPR,10 since it consists of 
primary particles with a size < 25 nm. However, the data provided by the manufacturer shows that the 
active substance will be an aggregate of primary particles with a size of 1-6 μm. It is therefore stated in the 
assessment report that the hazard and risk of the individual NPs of silicon dioxide were not evaluated in the 
dossier, since “Under conditions of normal handling and use, it is considered that aggregates are the 
smallest stable particles. In this context, data provided by the notifier and literature tend to show that 
liberation of primary particles and exposure to nano-object (material with one, two or three external 
dimensions in the nanoscale) is not expected during and after the intended biocidal application considered 
in this dossier”.18 
Silicon dioxide (as a nanomaterial formed by aggregates and agglomerates) and silver adsorbed on 
silicon dioxide (HeiQ AGS-20) are currently under review for PT 18 and PT 9, respectively.19, 20 For HeiQ AGS-
20, which consists of stable 1-50 μm particle aggregates containing primary particles in the nanoscale, the 
Biocidal Products Committee (BPC)18 has expressed the opinion that AGS-20 is to be regarded as the 
biocidal active substance as it is the result of a combustion synthesis process and not just a simple mixing of 
the two components and that a range for the silver content and silicon dioxide content should be added to 
further specify the active substance. They furthermore note that AGS-20 meets the definition of a 
nanomaterial under the BPR as it is a stable aggregate with primary nanoparticles complying with the 
number size distribution provision in the BPR and that the derogation of complex heterogeneous 
nanomaterials including nano-composites in recital 14 to Commission Recommendation 2011/696/EU does 
not apply to AGS-20, since it is a purely particulate materials despite of the fact that it is a composite. While 
not wanting to express their opinion on a possible nanospecification of AGS-20 prior to the evaluation 
phase of the active substance, the BPC does refer to the approval of nanoSAS and state that it could be 
outlined that AGS-20 is a stable aggregate with primary particles in the nanoscale with additional 
specification of particle size and volume specific surface area. The latter indicates that the SAS evaluation 
could create precedence when it comes to approval of nanomaterials.  
Other assessment reports specifically mention that they do not cover the nano-form of that 
active substance (i.e. ARs for basic copper (II) carbonate, copper (II) hydroxide and copper (II) oxide).21,22, 23 
The Competent Authority Reports (CARs)24 for copper carbonate, copper oxide and copper 
hydroxidespecifically mention that the nanoforms of these substances are not included in the reports. For 
instance, for basic copper carbonate, the assessment states that “the applicant is not currently placing 
nanoforms of basic copper carbonate on the market. Therefore, the submitted dossier and the finalised 
assessment report don’t cover potential nanoforms of this copper compound, should such forms exist.” 21  
 
5. Nanomaterials and the review programme on existing active substances  
Under the BPD a 10-year review programme was set up with the purpose of systematically examining all 
active substances already on the market. The outcome of the examination would either be an inclusion of 
the substance to the list of approved substances (Annex I, IA or IB of the BPD), or no inclusion and thereby 
a restriction of the marketing and use of the substance.7 The review programme on existing active 
substances initiated under the BPD is continued under the BPR and was expected to be finalized by May 
2014 (Art 89).10 In an amendment of the BPR it was decided to extend the review period until 2024 and to 
differentiate between the deadlines for the different product types.14 As stated in Article 86 of the BPR, 
active substances which were already approved and thereby included in Annex I of the BPD, should be 
deemed as approved under the BPR as well, and thus automatically included in the positive list (Art. 86).10 
As introduced above, a number of existing active substances are currently under review. It is, 
however, not indicated whether any of the active substances included in Annex II of Regulation (EC) 
1451/2007 are in nanoform, since NM-specific requirements were not included in the scope of the BPD, nor 
mentioned in Regulation (EC) 1451/2007.25 This results in different issues and uncertainties regarding the 
legal status of NMs under the BPR and the review programme, as pointed out by both Member States and 
the nano-industry, and clarification of this is therefore needed.10,26 
Nevertheless, considering the list of existing active substances that are currently under 
review, it is clear that at least some of them might be available in the nanoform, for instance, silver, 
copper, dicopper oxide and silicon dioxide. See Table 2 for substances being examined under the Review 
Programme that might be available in the nanoform and the Product Types that they have been notified for 
use in. 
 
Table 2: Substances being examined under the Review Programme27 that might be available in the 
nanoform and the Product Types that they have been notified to be used in. 
  PT1 PT2 PT4 PT5 PT7 PT9 PT11 PT18 PT21 
Silver  X X X   X   
Silver phosphate glass  X   X X    
Silver-Zinc-Zeolite  X X X X X    
Silver copper zeolite   X X X X X    
Silver adsorbed on silicon 
dioxide  
     X    
Silver zeolite  X X X X X    
Silicium dioxide        X  
Dicopper oxide         X 
Copper         X 
 
 
 
6. Active substances and the Nanodatabase  
At this point it is not entirely clear which commercially available articles in the EU have been treated with 
nanomaterials or incorporate a biocidal form of a nanomaterial. Similarly, it is not clear which biocidal 
products might be available in commerce. As described above, the BPR contains provisions that apply to 
active substances, biocidal products and articles, which incorporate a biocidal product or have been treated 
with a biocidal product. Following approval of the active substance, biocidal products can only contain 
active substances that have been approved for the specific use in the specific PT and articles can only be 
treated with active substances, which have been approved in the EU for that specific purpose. The only 
approved nanoform of an active substance in the BPR currently is silicon dioxide (for PT18), whereas silver 
adsorbed on silicon is under review (for PT9). However, it is well known that, for instance, nanosilver and 
nanocopper are used in consumer products because of their biocidal properties.28 Since 2012, we have 
maintained and updated a European nanoproduct inventory, The Nanodatabase,5 in collaboration with the 
Danish Ecological Council and the Danish Consumer Council. Out of the 2329 products containing 
nanomaterials, which are estimated to be on the European market, 342 contain nanosilver, 48 contain 
silicon dioxide, and six contain copper (Figure 1). Most of the products that use biocidal nanomaterials fall 
into the “health and fitness category” (for example, personal care products and clothing), “home and 
garden” (cleaning products) or “food and beverages” (food supplements, storage and cooking). Around 100 
products contain titanium dioxide, which can be considered as an active substance, but it must be noted 
that it is also widely used as a pigment.  
In about half of all the nanosilver-containing products in The Nanodatabase, the producers make 
antibacterial or antifungal claims. It is interesting that none of the products in this database seem to have a 
proper label according to the BPR rules to disclose that they contain nanomaterials including the word 
“nano” in brackets, following each reference to the given nanomaterial, and which specify the specific 
related risks. This is the case despite the fact that labelling is a key provision (Article 68)10 in the BPR for 
products marketed after 1 September 2013.  
7. Biocidal products and treated articles in The Nanodatabase  
The Nanodatabase5 contains 88 biocidal products in total, and most of them are representing product types 
1 and 2, i.e. disinfectants and algaecides, and human hygiene products, respectively (Figure 2). Such 
products include disinfecting sprays, air purifiers, cleaning products, biocidal paints and varnishes, etc. The 
nanomaterials that are the active substances in those biocidal products are primarily silver (46 products), 
with a few products containing silicon dioxide (3 products), and a large fraction of all biocidal products are 
containing nanomaterial of unknown identity (39 products). If the nanomaterial identity for the biocidal 
product is unknown, it means that the manufacturer is claiming both the presence of nanomaterials in the 
product and the biocidal properties of the product. 
 
When it comes to looking at biocidal products in different product categories in The 
Nanodatabase, it becomes apparent that most of the products fall into “home and garden” category, which 
is for the most part represented by different cleaning products, detergents and paints, corresponding to 
product type 2 – disinfectants and algaecides, according to the BPR (Figure 3).  
There are 202 nano-enabled treated articles reported in The Nanodatabase in total, and most of 
them (157) have nanosilver as the active substance (see Figure 4). Other nanomaterials used in treated 
articles include bamboo charcoal, which is used for such products as air purifiers and textiles, carbon, which 
is used for water filtration devices, and several products include nano iron, gold and titanium as an active 
biocidal substance. 
The largest fraction of the nano-enabled treated articles (79 %) that are found in The 
Nanodatabase, fall into “Health and Fitness” category, representing different textiles, personal care items, 
and food contact materials (Figure 5).  
 
 
8. Discussion and recommendations  
 
The present paper is one of the first studies that address the current uses of nanomaterials in biocidal 
products and treated articles. It describes how nanomaterials are regulated under the BPR and which 
nanomaterials might be used in biocidal products and treated articles based on the review programme and 
information about nanoproducts available in The Nanodatabase, 88 of which are considered to be biocidal 
products.  
Outset for our analysis was taken in the List of active substances and the List of substances under 
the review program. Regarding the List of active substances, it is unclear whether any of the substances 
might be in the nanoform as defined by the BPR as they might already have been assessed and approved 
under the BPD. As a consequence, they have automatically been included on the list of approved 
substances under the BPR not considering that they might be nanomaterials.29 In order to avoid confusion, 
the European Commission has to make it clear that active substances assessed and/or approved under the 
BPD that are in the nanoforms are not automatically approved under the BPR and therefore have to obtain 
their own approval and have to be subject to the nanospecific requirements of the BPR.  
A number of substances currently included in the review programme, such as silver, could be 
nanomaterials, but it is lack of clarity regarding the exact form of the active substances assessed and 
supported by the applicants and currently under review. The Commission has set procedures in motion to 
contact all participants in the review program in order to obtain information on the exact form of the active 
substance proposing that substances of which a notification is subsequently submitted to the Commission 
will be allowed to remain on the market until a decision on their approval has been established.29  
There are several nanomaterials, e.g. copper, on the List of active substances and the List of 
substances under the review program where producers and retailers of the nanoforms claim that the 
nanoforms of the material have biocidal properties despite the fact that the nanoform is specifically 
mentioned not to be part of the assessment report completed competent authority as part of the approval 
process. ECHA has called for producers and importers to come forward and sponsor the nanoforms of e.g. 
copper and deadline for this was 30 October 2015 One notification only has been received for a nanoform 
of silver. The European Commission is the process of making a non-approval decision which will clarify that 
apart from the nanoform of active substance explicitly mentioned in Annex II of the Review Programme 
Regulation (EU) No 1062/2014,27 no nanomaterial is supported under the review programme. This will 
again lead to the Commission being able to initiate the modification of the Review Regulation itself and in 
particular its Annex II so that only includes substances included in the review programme. As a result of this 
exercise only two nanoform of silver will remain in the review programme.30  
 
The success of these modifications is of crucial importance for the overall trustworthiness of the 
European Commission, ECHA and the BPR that the European Commission and ECHA are able to identify and 
put claims about biocidal properties to a halt for substances that are sold in the nanoforms, but which are 
not covered by the Biocidal Products Committee opinions on active substance approval.  
At this point it is not entirely clear which commercially available articles in the EU have been 
treated with nanomaterials or incorporate a biocidal form of a nanomaterial. Similarly, it is not clear which 
biocidal products might be commercially available. In our analysis of biocidal products and treated articles 
we took outset in The Nanodatabase and analyzed which nanomateirals were used and what product types 
the uses would fall under.  
In about 50% of all the nanosilver-containing products, the producers make antibacterial or 
antifungal claims which means that the product are likely to fall under the provisions of the BPR. However, 
in the present study it was not possible to determine whether nanomaterials were actually present in the 
products with claims about “nano” by looking at the labels of the products. It was furthermore not possible 
to evaluate whether the products claimed to have biocidal properties are actually effective as 
antimicrobials. 
Adequate labelling is a major problem and risks undermining the credibility of the treated article 
provisions in the BPR. The EU could learn from the nanoMark System implemented by the Industrial 
Development Bureau, Ministry of Economic Affairs in Taiwan in 2004 for certifying nanoproducts. The 
system was put in place to enhance the quality and image of products based on nanotechnology and 
protect consumer's rights while simultaneously promoting the development of a national nanotechnology 
industry.31 Specifically, the nanoMark should only be granted to “real nanoProducts” that are considered 
good enough for a specified level and use in order to avoid confusion and protect the right of consumers 
while also preventing “bad products from driving out good ones in a market glutted with nano-products of 
different quality”.31, 32 In order to receive the NanoMark certification and be allowed to wear the NanoMark 
label, tests have to be completed by qualified and verified laboratories validating the claims made by the 
manufacturers regarding the particle size and chemical constitution of the nanomaterials in their products 
and their advertised efficacy.33 39 companies and 1490 products have passed the NanoMark certification in 
the period from 2004 and 201434  and in 2012, the NanoMark had 41 NanoMark product verification 
standards including some that are relevant for the BPR, for instance photocatalytically active anti-bacterial 
tiles, lamps and coatings and nano silver antibacterial paint for indoor decoration, household decoration 
textiles, socks, sanitary ceramic ware, plastic toilet seat, plastic toilet tank parts.32,33,35 Ten years after 
implementation, it seems that the nanoMark system has not only helped the companies increase their 
corporate image and promoted "market sales", but has also allowed companies that participate in the 
system to increase the selling price of their products by 20%.36 This provides clear evidence that 
implementing nanospecific certification requirements in the BPR would enhance the overall enterprise 
competitiveness of the industry while also assisting in gaining consumer trust in the BPR and weed out 
products that claim to contain nanomaterials and have biocidal properties when they actually do not.  
There are a number of tools available to determine the presence of nanomaterials in biocidal 
products and treated articles, as well as to quantify the amount of the active substance in the product. 
Ideally the manufacturer should be able to provide necessary information regarding the primary size and 
total amount of the nanoparticles applied to the certain product, but this information is not always readily 
available. In the recent years there has been an increasing amount of scientific publications addressing the 
issue of the presence nanomaterials in consumer products and the uncertainties regarding their safety (e.g. 
37,38,39). To determine the presence of a biocidal substance is not the most challenging part, however, to 
verify that the substance occurs in its nanoform is a much more complex task to accomplish. Depending on 
what the product is – solid, liquid, or aerosol – there are different set of methods that can be applied to 
find NMs in the product. A recent review by Laborda et al.40 has compiled and described the experimental 
studies published to date that have attempted to determine the presence of NMs in different types of 
consumer products including several items with antibacterial and disinfection claims and properties, 
highlighting also a variety of analytical tools and sample preparation methods that can be used for 
quantification and characterization. For example, when it comes to such liquid samples as sunscreens, 
which most commonly use TiO2 or ZnO nanoparticles, it is possible to use electron microscopy (EM) in 
combination with electron dispersive X-ray spectroscopy (EDS) to find and identify the nanoparticles.41 
Alternatively, as one study has illustrated, single particle inductively coupled plasma mass spectrometry 
(spICP-MS) is also a powerful tool to both identify and quantify the nanoparticle content in such samples, 
as well as provide the size distribution of the particles in the sunscreen.42 The spICP-MS method as 
described by Dan et al.42 could also be applicable for a large number of personal care products that have to 
be tested for their NM content. Similar output is also possible with other tools such as asymmetric flow 
field flow fractionation (AF4) combined with ICP-MS or UV-Vis.43,44 Other products that have been 
addressed in the literature and experimentally investigated include various dietary supplements that 
contain Ag nanoparticles,45,46 disinfectant sprays with Ag or ZnO NPs47,48 and different food products such 
as e.g. chicken meat with Ag.49,50 So in general, even when it comes to analyzing NMs in very complex 
matrices and different types of materials, there are methods available to tackle the nanomaterial 
characterization and quantification issues. However, many of the methods require extensive sample 
preparation for e.g. NM extraction and accurate nanoparticle characterization, and many of the analytical 
tools are costly and therefore are only available in specialized research labs.  Therefore, it would be highly 
beneficial if manufacturers can provide necessary information about the pristine particles that are applied 
in the products, including the sizes and the quantity of the particles applied, as well as noting the location 
of the particles (suspended in liquid/solid, attached to the surface etc.). This would aid legislators, 
researchers and consumers to better understand the properties of the product. 
9. Conclusions 
 
The number of nano-enabled biocidal products and treated articles is increasing on the European market, 
according to the information available on The Nanodatabase.5 However, even though they advertise NM 
content, most of the products do not have specific labelling as required by BPR. Moreover, most of the 
utilized NMs are not yet approved by the BPR, illustrating the need for manufacturers to provide the 
specific information necessary to approve and register the substances according to the procedures 
highlighted in the BPR. It is of utmost importance for European Commission and European Chemical Agency 
to take steps to enforce their legislation and ensure proper labelling of biocidal products and treated 
articles that contain NMs. 
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